Medicine and Health Sciences Commons^™

Exploring The Role Of 4-Thiazolidinone Derivatives As Potential Cox-2 Inhibitors And Free Radical Scavenging Agents, Vikram Jeet Singh, Pooja Chawla

Research Symposium

Background: Cyclooxygenase-2 (COX-2) and free radicals has become an important target in the management of various pathological conditions including cancer and inflammation. The pyridine or thiazolidinone has become an emerging scaffold in the drug design and development of COX-2 inhibitors and free radical scavenging agents. 4-Thiazolidinone clubbed pyridine may potentiate each other activity and can emerge as a promising scaffold in the treatment of inflammation/cancer.

Methods: The present work reports synthesis and screening of 4-thiazolidinone-pyridine hybrids with substituted arylidene containing electron-donating group at 5^th position. The compounds were screened for their in-vivo anti-inflammatory activity using carrageenan-induced rat …

Erk Required For Lipopolysaccharide-Induced Tlr4 Internalization In Macrophages, Sara M. Reyna, Phoebe Fang-Mei Chang

Research Symposium

Background: Insulin resistance is associated with low circulating levels of lipopolysaccharide (LPS). Binding of LPS to Toll like receptor 4 (TLR4) leads to the internalization and trafficking of TLR4 resulting in activation of downstream signaling pathways. TLR4 internalization in macrophages leads to the activation of pro-inflammatory signaling pathways and production of factors linked to the development of insulin resistance. The extracellular signal-regulated kinase 1 and 2 (ERK1 and 2) are activated downstream of TLR4 and are associated with insulin resistance. We hypothesized that ERK1 and ERK2 regulate TLR4 internalization in macrophages when exposed to LPS.

Methods: We examined whether inhibition …

The Comorbidity Of Depression And Neurocognitive Disorder In Persons With Hiv Infection: Call For Investigation And Treatment, Karl Goodkin, Teresa H. Evering, Albert M. Anderson, Ann Ragin, Cynthia L. Monaco, Christina Gavegnano, Ryan J. Avery, Sean B. Rourke, Lucette A. Cysique, Bruce J. Brew

School of Medicine Publications and Presentations

Depression and neurocognitive disorder continue to be the major neuropsychiatric disorders affecting persons with HIV (PWH). The prevalence of major depressive disorder is two to fourfold higher among PWH than the general population (∼6.7%). Prevalence estimates of neurocognitive disorder among PWH range from 25 to over 47% – depending upon the definition used (which is currently evolving), the size of the test battery employed, and the demographic and HIV disease characteristics of the participants included, such as age range and sex distribution. Both major depressive disorder and neurocognitive disorder also result in substantial morbidity and premature mortality. However, though anticipated …